TrialCancer immunology, immunotherapy : CII2007

Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients.

Houssem Benlalam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.